Empirical_JJ Bayesian_JJ data_NNS mining_NN for_IN discovering_VBG patterns_NNS in_IN post-marketing_JJ drug_NN safety_NN
Because_IN of_IN practical_JJ limits_NNS in_IN characterizing_VBG the_DT safety_NN profiles_NNS of_IN therapeutic_JJ products_NNS prior_RB to_TO marketing_NN ,_, manufacturers_NNS and_CC regulatory_JJ agencies_NNS perform_VBP post-marketing_JJ surveillance_NN based_VBN on_IN the_DT collection_NN of_IN adverse_JJ reaction_NN reports_NNS -LRB-_-LRB- ``_`` pharmacovigilance_NN ''_'' -RRB-_-RRB- ._.
The_DT resulting_VBG databases_NNS ,_, while_IN rich_JJ in_IN real-world_JJ information_NN ,_, are_VBP notoriously_RB difficult_JJ to_TO analyze_VB using_VBG traditional_JJ techniques_NNS ._.
Each_DT report_NN may_MD involve_VB multiple_JJ medicines_NNS ,_, symptoms_NNS ,_, and_CC demographic_JJ factors_NNS ,_, and_CC there_EX is_VBZ no_DT easily_RB linked_VBN information_NN on_IN drug_NN exposure_NN in_IN the_DT reporting_NN population_NN ._.
KDD_NN techniques_NNS ,_, such_JJ as_IN association_NN finding_NN ,_, are_VBP well-matched_JJ to_TO the_DT problem_NN ,_, but_CC are_VBP difficult_JJ for_IN medical_JJ staff_NN to_TO apply_VB and_CC interpret_VB ._.
To_TO deploy_VB KDD_NNP effectively_RB for_IN pharmacovigilance_NN ,_, Lincoln_NNP Technologies_NNP and_CC GlaxoSmithKline_NNP collaborated_VBD to_TO create_VB a_DT webbased_JJ safety_NN data_NNS mining_NN web_NN environment_NN ._.
The_DT analytical_JJ core_NN is_VBZ a_DT high-performance_JJ implementation_NN of_IN the_DT MGPS_NNP -LRB-_-LRB- Multi-Item_NNP Gamma_NNP Poisson_NNP Shrinker_NNP -RRB-_-RRB- algorithm_NN described_VBN previously_RB by_IN DuMouchel_NNP and_CC Pregibon_NNP ,_, with_IN several_JJ significant_JJ extensions_NNS and_CC enhancements_NNS ._.
The_DT environment_NN offers_VBZ an_DT interface_NN for_IN specifying_VBG data_NNS mining_NN runs_VBZ ,_, a_DT batch_NN execution_NN facility_NN ,_, tabular_JJ and_CC graphical_JJ methods_NNS for_IN exploring_VBG associations_NNS ,_, and_CC drilldown_NN to_TO case_NN details_NNS ._.
Substantial_JJ work_NN was_VBD involved_VBN in_IN preparing_VBG the_DT raw_JJ adverse_JJ event_NN data_NNS for_IN mining_NN ,_, including_VBG harmonization_NN of_IN drug_NN names_NNS and_CC removal_NN of_IN duplicate_VB reports_NNS ._.
The_DT environment_NN can_MD be_VB used_VBN to_TO explore_VB both_CC drug-event_JJ and_CC multi-way_JJ associations_NNS -LRB-_-LRB- interactions_NNS ,_, syndromes_NNS -RRB-_-RRB- ._.
It_PRP has_VBZ been_VBN used_VBN to_TO study_VB age\/gender_JJ effects_NNS ,_, to_TO predict_VB the_DT safety_NN profiles_NNS of_IN proposed_VBN combination_NN drugs_NNS ,_, and_CC to_TO separate_JJ contributions_NNS of_IN individual_JJ drugs_NNS to_TO safety_NN problems_NNS in_IN polytherapy_JJ situations_NNS ._.
